Veracyte officer files notice to sell $145K stock

An officer of Veracyte, Inc. has filed a Rule 144 notice to potentially sell 3,254 common shares acquired via restricted stock units.

Rhea-AI Filing Summary

VERACYTE, INC. (VCYT) has a notice of proposed sale under Rule 144 filed on behalf of officer Ann McGuire. The notice covers the potential sale of 3,254 shares of Veracyte common stock through Morgan Stanley Smith Barney LLC, with an approximate sale date of September 4, 2026. The shares to be sold were acquired on September 2, 2026 as Restricted Stock Units from the issuer. The filing also lists Veracyte common shares outstanding as 80,390,731, which is a baseline figure, not the amount being sold.

Key Figures

Shares proposed for sale: 3,254 shares Aggregate market value: $145,356.18 Shares outstanding: 80,390,731 shares +2 more

5 metrics

Shares proposed for sale 3,254 shares Maximum number of Veracyte common shares covered by the Rule 144 notice

Aggregate market value $145,356.18 Value associated with the 3,254 Veracyte common shares in the notice

Shares outstanding 80,390,731 shares Veracyte common shares outstanding listed in the filing

Approximate sale date September 4, 2026 Approximate date of sale for the proposed Rule 144 transaction

Acquisition date September 2, 2026 Date the Restricted Stock Units underlying the shares were acquired from the issuer

Key Terms

Rule 144, Restricted Stock Units, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"Common | 09/02/2026 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 3254 | 145356.18"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for VERACYTE, INC. (VCYT)?

It discloses that officer Ann McGuire has filed a Rule 144 notice for the potential sale of 3,254 shares of Veracyte common stock through Morgan Stanley Smith Barney LLC, with an approximate sale date of September 4, 2026.

How many Veracyte (VCYT) shares are covered by this Rule 144 notice?

The notice covers a proposed sale of 3,254 shares of Veracyte common stock. This is the maximum number of shares indicated for potential sale in this Form 144 filing.

What is the aggregate market value of the Veracyte (VCYT) shares in this Form 144?

The filing lists an aggregate market value of $145,356.18 for the 3,254 shares of Veracyte common stock covered by the Rule 144 notice.

When were the Veracyte (VCYT) shares to be sold acquired?

The shares covered by the notice were acquired on September 2, 2026 as Restricted Stock Units from Veracyte, Inc. as the issuer.

How many Veracyte (VCYT) shares are reported as outstanding in this filing?

The filing reports 80,390,731 Veracyte common shares as outstanding. This number provides context on company size and is separate from the 3,254 shares covered by the proposed sale notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:34 PM EDT Accepted by SEC EDGAR 09/04/2026 - 04:33 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001914620
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	VERACYTE, INC.
SEC File Number	001-36156
Address of Issuer	6000 Shoreline Court, Suite 300 South San Francisco CALIFORNIA 94080
Phone	6502436300
Name of Person for Whose Account the Securities are To Be Sold	ANN MCGUIRE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3254	145356.18	80390731	09/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2026	Restricted Stock Units	Issuer			3254	09/02/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/04/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Ann McGuire
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)